Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation

We conducted a phase I-II study of transplantation conditioning with clofarabine-melphalan-alemtuzumab for patients with advanced hematologic malignancies. Ten patients were accrued to the phase I portion, which utilized an accelerated titration design. No dose-limiting toxicity was observed, and cl...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: van Besien, Koen, Stock, Wendy, Rich, Elizabeth, Odenike, Olatoyosi, Godley, Lucy A., O’Donnell, Peter H., Kline, Justin, Nguyen, Vu, del Cerro, Paula, Larson, Richard A., Artz, Andrew S.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3423318/
https://ncbi.nlm.nih.gov/pubmed/22079470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.10.041
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki